Introduction: Breast cancer is one of the most prevalent malignant neoplasms among women, representing a significant public health problem in both developed and developing countries. Early detection of the disease, particularly through mammography, is one of the most effective strategies for reducing its mortality, allowing the identification of lesions at early stages and enabling less aggressive treatments for patients. However, Brazil exhibits significant regional disparities in access to healthcare services, especially in the North and Northeast regions, which are historically marked by lower socioeconomic development and consequent health disadvantages. Objectives: To analyze the incidence of breast cancer and the coverage of screening procedures in the North and Northeast regions. Methods: This is a cross-sectional epidemiological study with a quantitative approach, based on data analysis obtained from the Departamento de Informática do Sistema Único de Saúde (DATASUS), focusing on the North and Northeast regions from 2015 to 2024. The study identifies the number of mammograms performed and their association with the incidence of malignant breast neoplasms during the specified period. Results: According to data from the Sistema de Informações Ambulatoriais do SUS (SIA/SUS), a total of 92,480 mammograms were performed in the North region and 527,875 in the Northeast region. During this period, 20,216 diagnoses of malignant breast neoplasms were recorded in the North and 131,548 in the Northeast, based on information from the Oncology Panel Brazil/DataSUS. The detection rate of malignant neoplasms was 21.86% in the North and 24.92% in the Northeast. These results demonstrate a notable diagnostic rate derived from screening examinations, reinforcing their importance in the early detection of breast cancer. Most diagnoses occurred among women over 40 years of age, according to the distribution of cases by age group. In the North region, the groups with the highest number of records were those aged 40–49 years, with 5,487 cases, followed by those aged 50–59 years, with 5,443 cases, and 60–69 years, with 3,943 cases, showing progressive reductions in higher age ranges. In the Northeast, the pattern was similar, with the highest concentrations in the age groups of 40–49 years (29,406 cases), 50–59 years (32,916 cases), and 60–69 years (24,972 cases). This concentration of diagnoses aligns with the ages at which mammographic screening is most recommended. Conclusion: A lower rate of diagnoses and mammograms was observed in the North region compared to the Northeast, which may be associated with factors such as a smaller female population in the North, as well as reduced accessibility and awareness of screening methods for neoplasia. Nevertheless, in the Northeast, screening through mammography has shown positive results, indicating active search and prevention among women. This highlights the need for continuous public awareness through policies that encourage medical follow-up and discussions on breast cancer in the regions mentioned.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
